Pulmonx (LUNG) Revenue (2019 - 2025)

Pulmonx (LUNG) has reported Revenue for 7 consecutive years, with $21.5 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Revenue rose 5.47% year-over-year to $21.5 million in Q3 2025; TTM through Sep 2025 was $91.7 million, a 15.59% increase from a year earlier, with the FY2024 full-year figure at $83.8 million, up 22.01% from the prior year.
• Revenue was $21.5 million for Q3 2025 at Pulmonx, down from $23.9 million in the prior quarter.
• Over five years, Revenue peaked at $23.9 million in Q2 2025 and troughed at $9.2 million in Q1 2021.
• A 5-year average of $17.0 million and a median of $17.2 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 232.24% in 2021 and grew 1.82% in 2022, its largest moves.
• Over 5 years, Revenue stood at $13.7 million in 2021, then rose by 12.53% to $15.4 million in 2022, then grew by 24.98% to $19.3 million in 2023, then climbed by 23.28% to $23.8 million in 2024, then decreased by 9.52% to $21.5 million in 2025.
• The last three Revenue figures came in at $21.5 million (Q3 2025), $23.9 million (Q2 2025), and $22.5 million (Q1 2025), per Business Quant data.